Pedro Torrellas Ruiz in Humacao, Puerto Rico

Home Puerto Rico Humacao

Pedro Torrellas Ruiz has Pulmonary Disease as his primary medical specialty. Their primary office is: 47 Ave Font Martelo in Humacao, Puerto Rico. They attended Sorry, his university is not listed and graduated in 2004 (around 20 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.

Pedro A Torrellas Ruiz Office Phone and Directions

Pedro Torrellas Ruiz
47 Ave Font Martelo
Humacao, Puerto Rico 00791
787-474-0406

Patient Ratings
Please rate your experience with Pedro Torrellas Ruiz below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 787-474-0406

Enter a starting address:

Healthcare Info for Pedro Torrellas Ruiz

Medical School: Sorry, his university is not listed
Graduation Year: 2004
The Primary Medical Specialty for Pedro Torrellas Ruiz is listed as: Pulmonary Disease
Approximate Years of Experience: 20
PAC (PECOS ID)#: 0941451462
NPI #: 1013168616
NPI Created On: 10/02/2008
NPI Last Updated Listed as: 11/09/2023
Primary Taxonomy Code: 207R00000X

URL not found for state: PR licensing board.
License Number:
18130
Listed Gender: Male

Procedures, Services, Charges

Services and Procedures include:

Established patient office or other outpatient visit, typically 15 minutes
Initial hospital inpatient care, typically 70 minutes per day
Subsequent hospital inpatient care, typically 35 minutes per day

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $17

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788932571

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Cardiovascular & Metabolism

Name of Drug #1: XARELTO

Open Associated Drug #1: 50458-580-30